Sagespring Wealth Partners LLC Buys 214 Shares of IQVIA Holdings Inc. $IQV

Sagespring Wealth Partners LLC raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,075 shares of the medical research company’s stock after acquiring an additional 214 shares during the quarter. Sagespring Wealth Partners LLC’s holdings in IQVIA were worth $957,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd boosted its position in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 131 shares in the last quarter. Golden State Wealth Management LLC boosted its holdings in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after buying an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new stake in shares of IQVIA in the 1st quarter valued at about $33,000. Trust Co. of Toledo NA OH acquired a new stake in IQVIA in the second quarter valued at approximately $39,000. Finally, Larson Financial Group LLC grew its holdings in IQVIA by 109.9% in the first quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock worth $48,000 after purchasing an additional 144 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company’s stock, valued at $557,352.30. The trade was a 15.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares of the company’s stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on IQV shares. Truist Financial lifted their price target on shares of IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. Robert W. Baird raised their price objective on IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 23rd. Redburn Partners set a $214.00 price target on IQVIA in a research note on Wednesday, September 3rd. UBS Group upped their price objective on shares of IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a report on Wednesday, July 23rd. Finally, Evercore ISI lifted their target price on shares of IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $234.57.

IQVIA Trading Down 0.7%

IQVIA stock opened at $203.38 on Thursday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $237.21. The company has a market capitalization of $34.58 billion, a price-to-earnings ratio of 29.43, a price-to-earnings-growth ratio of 2.25 and a beta of 1.32. The stock has a 50-day moving average price of $190.38 and a 200 day moving average price of $168.79.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. During the same period in the previous year, the business posted $2.64 EPS. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.